ASCO 2010 - Erweiterung der standards durch molekulare therapien? Ein kongressbericht der 46.jahrestagung der American society of clinical oncology, Chicago 4-8.6.2010

Translated title of the contribution: Conference report on the 46th annual meeting of the American society of clinical oncology, Chicago June 4-8, 2010

L. C. Hanker, K. Schwedler, E. Ruckhäberle, M. Kaufmann


At the recent ASCO meeting the focus was on the surgical and radiotherapeutic treatment of breast cancer. The final results of the NSABP B-32 trial were presented, which confirmed the equivalent safety of sentinel lymph node biopsy (SLNB) compared to axillary node dissection. These surprising results of the ACOSOG Z0011 trial could influence the standard of care because they do not support routine axillary node dissection in the case of positive SLNB. Additionally, it could be shown that the presence of micrometastatic lymphatic disease as demonstrated by immunohistochemistry alone does not have a prognostic impact. Intraoperative radiotherapy may be a new option in radiotherapy because of its low toxicity rate and comparable local control at 24 months' follow-up based on the results of the randomized TARGIT trial. Moreover the CACGB 9343 trial only showed a small benefit of radiotherapy in elderly patients (> 70 years) after breast conserving therapy. The pooled data analysis of the BRITS and DESTINY trials revealed a therapeutically highly relevant rate of receptor discordance in the metastatic setting. However, use of the multityrosinkinase inhibitor sunitinib in combination with capecitabine or docetaxel was disappointing. In contrast a large meta-analysis confirmed the positive impact of bevacizumab on progression-free survival (PFS). The new molecular therapeutics such as PARP inhibitors and T-DM1 will have to be investigated in more detail. In gynecological carcinomas there was finally a trend towards targeted therapies. A significantly better PFSwas reported for primary ovarian cancer after maintenance therapy with bevacizumab compared to the standard therapy. Moreover the combination of carboplatin with PLD or gemcitabine might represent an alternative regimen in first-line treatment. New and promising substances such as PARP inhibitors, peptibodies and immunocon-jugate drugs are currently being tested for the treatment of recurrent ovarian cancer. The use of new sequential radiochemotherapies and antiangiogenetic agents has shown encouraging results in the treatment of cervical and endometrial cancer.

Translated title of the contributionConference report on the 46th annual meeting of the American society of clinical oncology, Chicago June 4-8, 2010
Original languageGerman
JournalGeburtshilfe und Frauenheilkunde
Issue number8
Pages (from-to)619-624
Number of pages6
Publication statusPublished - 2010


Dive into the research topics of 'Conference report on the 46th annual meeting of the American society of clinical oncology, Chicago June 4-8, 2010'. Together they form a unique fingerprint.

Cite this